Ohio’s July Medical Cannabis Sales Set New Record – Cannabis Business Times

Industry stakeholders by and large support the House Committee on Energy and Commerce passing on a voice vote a modified version of the Medical Marijuana Research Act of 2019. While there is no scheduled vote on the bill in the full House as of press time, the fact that the bill made it out of committee on a bipartisan vote signals a political tide change for cannabis research.

“Whatever our views on marijuana legalization as legislators, we all ought to support the collection of scientific data to guide our decisions,” tweeted Rep. Morgan Griffith (R-VA), a cosponsor of the bill, following the Sept. 9 committee vote. “This bipartisan legislation would make long-overdue improvements to the Fed Govt’s policies on marijuana research. It would advance the work of scientists and provide more reliable information about any benefits and harmful consequences that result from medicinal marijuana use.”

The Medical Marijuana Research Act would amend the Controlled Substances Act to establish a new, separate registration process to facilitate research with cannabis for medical purposes; direct the Food and Drug Administration (FDA) to issue guidelines on the production of cannabis from authorized researchers and manufacturers; ensure all medical cannabis researchers are in compliance with FDA drug development standards; and make available cannabis from state-authorized cannabis programs, under certain conditions.

According to the amended bill, the Secretary of Health and Human Services “shall offer to qualified marijuana researchers marijuana products available through State authorized marijuana programs that are consistent with the guidance issued under subsection (c).” That guidance shall be issued no later than 180 days after the enactment of the bill, according to the proposed law.

“There is a strong need to better understand the medicinal benefits of marijuana, but researchers don’t have the tools necessary to conduct proper, science-driven research,” said rep. Debbie Dingell (D-MI) in a statement. Dingell is another cosponsor of the bill. “That research [r]equires us to remove outdated barriers that prevent research. Doing so will improve our understanding of medical marijuana and provide additional treatment options for millions of patients.”

In a press release, NORML Deputy Director Paul Armentano said that granting researchers access to cannabis products produced in state-sanctioned markets “will not only facilitate and expedite clinical cannabis research in the United States and provide important data regarding the safety and efficacy of real-world products, but it will also bring about a long overdue end to decades of DEA stonewalling and interference with respect to the advancement of our scientific understanding of the cannabis plant.”

The Scottsdale Research Institute (SRI) has been one of many organizations trying to get the Drug Enforcement Administration (DEA) to speed up its research license process, going so far as to suing the DEA for slowing down the licensing process for federal cannabis research licenses. The institute, led by cannabis researcher Dr. Sue Sisley, “enthusiastically supports the bipartisan Marijuana Research Act of 2019,” it said in a Sept. 9 letter to the House Energy and Commerce Committee.

“Unlike other bills, if enacted, H.R. 3797 promises to be a very significant step forward for improving marijuana research,” the letter continues. “It directly addresses the core obstacles that DEA says prevent it from moving forward in approving additional researchers, including issues relating to the Single Convention on Narcotic Drugs. SRI also applauds the Amendment … that would permit researchers to access marijuana from state-legal dispensaries.”

In January, the American Psychological Association (APA) offered testimony to the House Energy and Commerce Committee on “Cannabis Policies for the New Decade” in which the association called for the committee to “take immediate action to facilitate critically needed cannabis research.”

In a statement to CBT, Dr. Jaime Diaz-Granados, PhD, the APA’s deputy CEO and acting chief scientific officer, said the organization “is pleased to see the modified version of this bill moving forward. It is critically important for the scientific community to gain access to the cannabis products available from state dispensaries to better understand the effects of cannabis as it is consumed in the real world. APA hopes that the Department of Health and Human Services and the Department of Justice will find a way to make this work.”

The American Medical Association also has expressed support for increased access to cannabis for research purposes. In an issue brief from its 2020 Medical Student Advocacy and Region Conference, the AMA backed the Senate’s Cannabidiol and Marijuana Research Expansion Act, another bill whose goal it is to reduce regulatory barriers to conducting research on medical cannabis. (CBT reached out to the AMA for comment on the Medical Marijuana Research Act of 2019, which did not return comment as of press time.)

Currently, only the University of Mississippi is licensed to produce medical cannabis for the National Institute on Drug Abuse (NIDA) Drug Supply Program. Critics of this system have denounced the quality of that product compared to material produced in state-sanctioned systems, adding that the chemical composition of products produced at Ole Miss resembles hemp more than what is available in states with medical and/or adult-use cannabis programs.

E-Cigarette Shopping Platform, Damp-e, Officially Adds Vaporizer to Product Assortment – Press Release – Digital Journal

AMSTERDAM – September 18, 2020 – (Newswire.com)

Damp-e, a Netherlands-based e-cigarette platform that carries everything from e-cigarettes to vapes, this week announced they have officially added vaporizers to their product offering.

Continuously expanding their online product offering to meet the demands of consumers, Damp-e carries pods, e-liquids, aromas, mods, evaporations, coils, do-it-yourself parts, e-cigarettes, and now vaporizers.

“Vaporizers have become a major part of the e-cigarette world today, which is why their addition to Damp-e just made sense,” said Mr. Dave Westerveld, President of Damp-e. “Damp-e will now carry both a portable vaporizer, as well as a table vaporizer.”

Defining a vaporizer as a specialized device that can be used to vaporize extracts or herbs, the Damp-e vaporizer selection is all about evaporation with no combustion. The absence of combustion in the process means the vaporizer is less harmful than regular smoking alternatives. No tar is released during combustion, sparing the lungs of dangerous ingestion.

“Vaporizers can be used with weed, hash and other herbs, depending upon the user’s preference,” said Mr. Westerveld. “Check carefully what type of vaporize technique that works with the device before ordering it. Spread the word on the addition of vaporizers to the Damp-e selection today.”

Damp-e also provides visitors with access to their e-cigarette specialists that are on-call to answer every question. The specialists will also go over how to use the products properly and safely if the buyer is new to the world of vapes.

For those wondering more about the world of vaporizers, Damp-e specialists are equipped with the latest knowledge for safe usage.

To check out the new vaporizer selection, visit: https://damp-e.nl/vaporizer

Press Release Service by Newswire.com

Original Source: E-Cigarette Shopping Platform, Damp-e, Officially Adds Vaporizer to Product Assortment

Global $5.3 Bn Cannabidiol (CBD) Oil Market to 2025 – PRNewswire

DUBLIN, Sept. 18, 2020 /PRNewswire/ — The „Global Cannabidiol (CBD) Oil Industry Report 2020” report has been added to ResearchAndMarkets.com’s offering.

The global market for cannabidiol (CBD) oil should grow from $967.2 million in 2020 to $5.3 billion by 2025, at compound annual growth rate (CAGR) of 40.4% for the period of 2020-2025.

The global CBD market is anticipated to grow at a strong rate over the forecast period owing to the growing adoption of CBD-based products for treating various medical conditions.

This report covers a range of products. This study will enable readers to understand and gain insights into the current market and will forecast changing market scenarios. The data provided can help users understand which market segments are expected to grow at the highest rates, along with factors driving growth and limiting growth, key opportunity areas, and more.

The global CBD oil market is mainly driven by growing research funding for cannabinoid research, legalization of CBD in various regions and the rising occurrence of chronic diseases and related complications. However, the adverse effects associated with cannabis and stringent government policies may slow the growth of the market.

The major operational strategies adopted by key competitors include R&D activities, establishment of joint ventures, collaborations, partnerships, product launches, and mergers and acquisitions. R&D activities and product launches are the topmost strategies to improve market position and brand image. The CBD oil market is a highly competitive market with the presence of many national, regional and local companies. Demand in the market calls for both cost and product differentiation, continuous product development and upgrades to assure and sustain profitability.

Hemp-derived products are the largest segment in the CBD oil products market. CBD oils are primarily used in pharmaceutical, food, cosmetic and other industries. The cosmetic and food industry segments accounts for more than half of the market. However, the pharmaceutical industry segment is expected to expand significantly, with a higher CAGR from 2020-2025. Regionally, North America captured the largest share of the CBD oil market in 2019. However, Asia-Pacific is one of the fastest-growing regions.

Key Market Projections

  • The hemp-derived segment market for cannabidiol (CBD) oil should grow from $516.3 million in 2020 to $2.9 billion by 2025, at a CAGR of 41.5% for the period of 2020-2025.
  • The marijuana-derived segment market for cannabidiol (CBD) oil should grow from $450.9 million in 2020 to $2.3 billion by 2025, at a CAGR of 39% for the period of 2020-2025.

Report Scope

This report offers a detailed, competitive outlook including market shares and company profiles of key participants. Key players profiled in the report include: Medical Marijuana Inc., Isodiol International Inc., ENDOCA, Elixinol Global Ltd., CV Sciences Inc., CBD American Shaman, Canopy Growth Corp., Aurora Cannabis and others.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Cannabis Definition
  • Cannabis Cultivation
  • THC, Other Cannabinoid Compounds and Their Mode of Action
  • Natural Cannabinoids
  • Synthetic Cannabinoids
  • Physiological Effect of Cannabinoid Compounds
  • Cannabis: Addiction and Other Negative Side Effects
  • Hemp, Cannabinoids and Related Industry Sectors
  • Legality of Cannabis Use
  • Cannabis Market Overview

Chapter 4 Market Dynamics

  • R&D Trends, Clinical Trials and FDA Approvals
  • Market Drivers
    • Growing Geriatric Populations
    • Legalization
  • Market Restraints
    • Counterfeit CBD Products

Chapter 5 Market Breakdown by Product Type

  • Introduction
  • Market Insights and Trends
  • Hemp-Derived CBD Oil
  • Overview
  • Marijuana-Derived CBD Oil
  • Overview

Chapter 6 Market Breakdown by Application

  • CBD and Its Applications
  • Market Size and Forecast
  • Pharmaceutical
    • Medical Marijuana as a Therapeutic Treatment
    • Medical Cannabis as Pain Medication and Alternative to Opioids
  • Food
  • Cosmetics
  • Others

Chapter 7 Market Breakdown by Region

Chapter 8 Regulatory Structure

  • Regulatory Structure of Cannabis in the U.S.
  • Regulatory Structure of Cannabis in Canada
  • CBD Oil Regulations in Europe
  • CBD Oil Regulations in Asia

Chapter 9 Competitive Landscape

  • Overview
  • Key Developments

Chapter 10 Company Profiles

  • Aphria Inc.
  • Aurora Cannabis Inc.
  • Canopy Growth Corp.
  • CBD American Shaman
  • Charlotte’s Web Holdings Inc.
  • CV Sciences
  • Elixinol Global Ltd.
  • Endoca
  • GW Pharmaceuticals plc
  • Isodiol International Inc.
  • Medical Marijuana Inc.
  • Tilray

For more information about this report visit https://www.researchandmarkets.com/r/vc78ut

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Why Aren’t There Any Standards For Cannabis Grow Rooms? – Benzinga

This article was originally published on Cannabis & Tech Today, and appears here with permission.

Just as the cannabis industry has grown at a rapid rate over the past five years, the grow room environment has also experienced significant evolution.

Growers are seeking to produce massive harvests and secure a place in the market, and in doing so are coming up against some major challenges associated with producing at scale.

This is a new frontier for many and a new field that requires different ways of thinking.

The “Secret Sauce” Mentality

One of the top challenges with scaling up cannabis production is the lack of standards in place.

It’s seriously hurting the industry right now by contributing to an information vacuum, especially as it relates to HVAC systems.

In the mainstream, engineers rely on proven and documented standards in order to properly handle buildings they are not familiar with.

An example are codes published by the American Society of Heating, Refrigeration and Air Conditioning Engineers (ASHRAE).

However, ASHRAE’s codes are geared towards residential and commercial buildings that are primarily designed for humans.

There are currently no ASHRAE standards that relate directly to indoor plant environments and few of their standards are sufficient to address the unique needs of these spaces.

Even the folks who think they have found the answers to the challenges posed by commercial cannabis production are not inclined to share information or insights.

This “secret sauce” mentality has exacerbated the challenges by ensuring no research- or data-sharing occurs in the industry.

If this secrecy continues, there can be no hope for developing industry standards and best practices.

As a result, engineers are without guidance as they get involved in the design and construction of modern grow rooms.

They wind up inventing solutions based largely on guesswork and the application of best practices from other environments or industries.

Standards In Any Industry Are Critical.

They are a set of principles that everyone has agreed on and can be followed uniformly to ensure ideal outcomes.

As the International Standards Organization says, standards answer the important question, “What is the best way of doing this?”

You may think some standards would have been created in the 25 years of medical cannabis.

While it’s certainly true that some things have changed since that industry got started, it isn’t necessarily true that the experience of the industry has translated into formalized guidelines.

Nor would those standards reflect the extraordinary advancements made in industry technologies just in the past couple of years.

The main standards borne out of medical grows are governmental regulations relating to quality of crop and specific chemical contents.

But these are of little help to someone building a new operation today with questions relating to facility design and operation.

The medical grows of before are not necessarily similar to what is being built today, especially for adult use grows — which, as a reminder, are expected to be the fastest-growing market segment in cannabis for the next few years.

The American Society of Agricultural and Biological Engineers (ASABE) has taken notice of the vacuum that exists today and has partnered with ASHRAE to create a new guideline for indoor growing environments: ASABE X653 guideline “Heating, Ventilating, and Air Conditioning (HVAC) for Indoor Plant Environments without Sunlight.”

This guideline is intended to provide clarity for engineers regarding the design and operation of isolated indoor plant environments, and hopefully install a new standard for engineers and grow operators to base their designs off of.

Learn more about HVAC design, specification, selection, installation, and operating, and order your free copy of Getting Grow Rooms Right at AgronomicIQ.com/book.

Read the original Article on Cannabis & Tech Today

Benzinga‚s Related Links: 

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Introducing the 0.00 Percent THC Cannabis Variety – DOPE Magazine – DOPE Magazine

Just when you thought you had seen it all in the wonder world of cannabis—one company just released a new variety of cannabis that they claim contains 0.00 percent THC. According to a September 15 press release, Orlando-based Bazelet Oglesby is taking an entirely new approach to cannabis marketing—releasing a plant without the prime cannabinoid responsible for heady, psychoactive effects.

The company is now introducing a new plant variety: Cannabis America, which is “100% genetically-free of the psychoactive and illegal compound delta-9-Tetrahydrocannabinol [THC].”

The team behind Bazelet Oglesby utilized tissue culture development in conjunction with molecular biology in genomics laboratories at universities located in both the US and Israel, which helped them to establish a genetic and genomics library. This, they say, ensures that the plants contain no traces of THC.

“Cannabis America plants have as much THC as wheat, corn or potatoes,” stated Gary Hennen, who serves as director of Bazelet Oglesby and president of Oglesby Plants International. He continued, “The Cannabis America plant variety is 100 percent THC-free and will help expand hemp production exponentially, particularly here in the US. Farmers who have been reluctant to grow Hemp for fear of possessing an illegal controlled substance can now be a part of the hemp economy without fear of breaking the law and losing their investment.”

Both cannabis grown for recreation and hemp are descended from the same genus and the same species, and separated only by THC content (and a handful of other characteristics). The appeal of cannabis plants free of THC is ideal for children suffering from epilepsy, for instance. Charlotte’s Web—a prime example of low-THC/high-CBD cannabis—was developed by the Stanley Brothers and named after Charlotte Figi, who was a source of inspiration behind the medical cannabis movement. Since then, several other low-THC strains have gained popularity in recent years.

The variety Cannabis America could be used for a variety of applications. However, it may be most useful as medical applications for people who need CBD without any traces of THC.

Crackdowns on hemp farms have been initiated based on minute variations in THC content, and based off of only tiny samples that represent entire crops. “The definition of hemp does not automatically exempt any product derived from a hemp plant, regardless of the delta-9-THC content of the derivative,” the Drug Enforcement Administration (DEA) states. “In order to meet the definition of ‘hemp,’ and thus qualify for the exemption from Schedule I, the derivative must not exceed the 0.3 percent delta-9 -THC limit.”

Considering that the DEA’s definition of hemp is draconian for farmers who accidentally grow hemp with too much THC, thus losing thousands of dollars, Bazelet Oglesby officials hope that some farmers who were reluctant to join the hemp industry will reconsider.

A patient’s guide to medical cannabis certifications in Missouri – Greenway

Over the past several months, I have had multiple family members, friends, and business associates ask me about the recent DHSS investigations into fraudulent medical cannabis certifications.  They ask me how this could happen, what the ramifications will be to our industry, and most importantly, how can we prevent such actions in the future.  The honest answer, I tell them, is that while there are certainly ways to improve the safety and security of medical cannabis certification process, not all bad actions can be predicted or prevented, and some level of risk will always remain.  The good news is, there are some simple questions patients can ask themselves when selecting a physician or group for medical cannabis certification to ensure that they receive their certification in an ethical, private, and fully legally compliant manner.  Even better, the questions apply not just to medical cannabis certifications, but also to any situation when choosing a medical practitioner to provide for your health!  To help, here are some examples of questions I would ask myself when choosing a doctor:

Who is the physician with whom you will be meeting?  Will you be able to reach this person later if you have questions or need follow-up care? Are they local to Missouri or based out of state?  Do they have a regular medical practice with an office where you can be seen in person, or are they only available online?

Since the legalization of medical cannabis in Missouri, there has been an explosion of websites online advertising medical cannabis certification.  I personally cringe when I see an ad with the phrase “one of our licensed doctors” in it, because largely that is code for the entity being a profit-driven organization which is likely not physician-run, potentially based out of state, which has frequent turnover of physicians, and is purely driven to maximize the number of certifications provided in a short-term profit-grab.  It is in the patient’s best interest, however, to select a physician with demonstrated commitment to the Missouri medical cannabis segment, who is ethical, and who is properly motivated by the goal to care for patients, not just take their money. There are many physicians in our state who run patient-centered professional medical practices which cater to the cannabis community, who understand the legal aspects of medical care such as HIPAA compliance, maintaining appropriate malpractice insurance, proper record keeping with a compliant electronic medical record system, and who are committed to providing health care to the cannabis community, whether through medical certifications or primary health care services.

Is the physician or practice ethical? What is their reputation in the Missouri medical cannabis community?

   

In medical school, every physician is educated in medical ethics.  Ideally, for a medical practice to be considered “ethical,” it must respect all four principles: autonomy, justice, beneficence, and non-maleficence.  For the lay person, this comes down to 1) Does the practice or physician allow the patient to make their own informed decision, free of coercion, after educating them about the risks or benefits of a certain course of treatment, 2) Is the care being provided with the intent of benefitting the patient involved, and 3) Is there a risk of harm to the patient or society which should prevent certain therapies being employed?  What this means, is that every physician has the ethical obligation to meet directly with the patient, inform the patient of the risks and benefits of a potential therapy, and work together to make an informed, collaborative decision in providing care that is in the patient’s best interests.  It also means that a physician “should do no harm,” meaning if a therapy is likely to make a condition worse or otherwise harm a patient, it should not be provided, and the physician should have the courage to withhold such care if ethically indicated.  In the field of medical cannabis certifications, this means that at times, patients are denied certifications, not just rubber-stamped through in pursuit of a quick buck.

Is the physician or practice established, will they be around to provide care for years to come? Is the physician experienced or knowledgeable about cannabis?

These are admittedly hard questions to answer right now – we have already seen many groups come and go over just the past year, and there is no recognized medical subspecialty for cannabis medicine.  It is becoming clearer, however, that there is a core group of physicians and medical practices dedicated to the Missouri medical cannabis community, practices which are physician-run, Missouri-based, and borne out of regular medical practices that have served their communities for years before expanding into cannabis medicine and medical cannabis certifications.  These physicians have joined national organizations, such as the Society of Cannabis Clinicians, actively seek out educational opportunities in cannabis medicine, and employ the considerable experience they already have in dealing with the many certifiable medical conditions, such as chronic pain, with the added tool of medical cannabis.

The take-home message is this: as a patient, your interests are best served by selecting a physician with whom you can discuss your medical condition, review any risks of cannabis therapy, and develop a collaborative relationship for your healthcare moving forward. The risk of fraud is minimized when you know the physician’s name, are able to reliably get in touch with them after certification, and when they are preferably based in Missouri with a track record of providing quality medical care in the community.  They should be knowledgeable about cannabis, take the time and be able to answer your questions, be discerning enough to request records when appropriate, and even deny certification if ethically indicated.  By selecting a physician committed to serving your healthcare needs in the manner described above, you not only improve your own health, but support the building of a strong, respected Missouri medical cannabis community at large.

Medical cannabis companies cleared for London stock market – The Guardian

Medicinal cannabis companies have been cleared by the UK’s financial regulator to float on the London Stock Exchange but firms that sell marijuana to recreational users will still be banned.

The Financial Conduct Authority said businesses that grow and sell recreational cannabis, even in countries such as Canada where it is legal, cannot list in London because of the Proceeds of Crime Act. Income from the sale of cannabis and cannabis oil outside the UK could constitute “criminal property” under the act, because it covers conduct abroad that would constitute a crime if it happened in the UK.

But the regulator said UK medical cannabis firms could float in London, as could overseas firms, although they would have to satisfy the regulator that they should be allowed to do so because of the more nuanced legal position.

The rules for overseas firms are complicated by the UK’s restrictive regulatory environment for medicinal cannabis, legalised in 2018. Cannabis growers require a licence from the Home Office, while any imports of the drug require patients to get a prescription first.

The FCA said regulations, which limit the extent to which medicinal cannabis is being used in the UK, meant overseas firms could not automatically be granted the right to list in London, even if they only sold a medical product. While firms might have a licence to sell in other countries, that did not mean they would be able to secure the same permissions from the Home Office, the regulator said.

“For medicinal cannabis and cannabis oil companies with overseas activities, the company will need to satisfy us that their activities would be legal if carried out in the UK,” the FCA said. “We will also need to understand the legal basis of the company’s overseas activities, for example the nature of the local licensing and the licences the company holds.”

Despite the complex position for overseas producers, the fast-growing cannabis industry is expected to celebrate the clarity from the markets regulator, which will help firms tap funding from new investors.

Nick Davis, chief executive of law firm Memery Crystal, which counts cannabis companies among its clients, said: “This is great and overdue news for the medicinal cannabis sector in the UK, both for medicinal cannabis companies themselves, but also for patients, who have yet to receive easy access to the products they need.

“Our firm, and a number of our clients, have worked hard over the past few years to have medical cannabis companies admitted to the London markets. With greater clarity from the FCA we hope investors will also support companies coming to market to drive the sector forward.”

5 Free-Wheeling Questions With GotBars510 Legal Craft Cannabis Entrepreneur – Forbes


I’ve always believed that the best stories in cannabis yet to be told were the ones that revealed themselves without saying too much. The plant has that essential effect and friends that I’ve made (and the ones not yet met) within this often silent craft will all say the same thing. Sometimes what you might want to say is best left unsaid in weed. It’s just how it we have survived for so long.

Our essential medicine is still illegal in many places. Cannabis is a powerful curative, but physically benign plant has been greatly misunderstood over the past seventy-five years or so.

My experience with the emotional reasonings surrounding cannabis are deep and authentic. I can picture the event as clearly as yesterday. Growing up in the western leafy suburbs of New York City, cannabis was both celebrated by my long-haired friends in prep school, trotting off to NYC to see Grateful Dead shows at Madison Square Garden and coming home really late, only to be chastised by our parents for “smelling like weed”. They never let me forget that weed was illegal. And still is in New Jersey.

This experience of being yelled at for smoking cannabis is the reason why cannabis has suffered much by stigmas over the past decades. Our parents hated cannabis because they couldn’t accept that cannabis had healing properties. All they saw was getting high or stoned or whatever they said at the time. It was mostly that smoking cannabis will prevent you from becoming successful. How we would never amount to anything. It’s refreshing to meet and eMeet young, vibrant cannabis entrepreneurs who see the benefits of the plant and the healing.

How wrong they were to assume back in the 1970’s that cannabis wouldn’t bring success. I’ll let my interviews with successful cannabis entrepreneurs speak volumes without saying a word. That is success.

Warren Bobrow=WB: Please tell me where you are from? Where now? Why cannabis instead of law or medicine, or the arts? When was the first time that you discovered the plant? 

GotBars510: What’s up to all my people out there. My government name is Joey but everyone in the Bay (SF Bay Area) where I’m born and raised and still reside refer to me as GotBars510. I discovered weed at the age around 11-12 yrs old while I was in middle school as a 6th grader. I always used weed to self medicate only didn’t realize it until I got more into the legalization and learned how the plant benefited me. Being as how it is legal, it has been and always will be my choice to not only medicate, but recreationally enjoy on a daily, or should I say hourly basis, ha ha ha.

WB: What are you known best for? What is the difference between medical cannabis and recreational cannabis? Why does the recreational consumer chase THC? 

GotBars510: The thing I’d say I’m best known for that separates me from most other people like myself is the fact that I don’t really put anything on what I do. I’m just a real live stoner. I can’t be bought, I am not a sellout, I just promote what I like, and on social media I show what I do. No acting, no pretending. To me, that’s what weed is all about. There has always been a line everyone tried to define between medicinal cannabis and recreational weed, but for me, it’s all the same unless you really try to sit me down to explain the difference. I think people on either side of that line smoke for the same reason people wear glasses, to improve their view of the world. 

WB:What are your six and twelve month goals? What obstacles do you face? Tell me about what you do for your company? 

GotBars510: If you had to ask me what my goals where both short and long term, it’s pretty simple. I just want to work with as many farms and hash companies that I can to share with the masses. I have homies who own so many clubs that always ask what it is I’m smoking, that I decided to do these collaborative projects so that I could put my stamp on a package for everyone to grab and share. All my packages feature the companies I’m involved in too. We go by the BrokeBoyz which is a term we use to not forget where we came from, Terpenstein which is a hash company my very good homie and mentor I refer to as my “Street Pops” who got me in the game with, and of course my own name which is my brand GotBars510. We literally act as brokers for any products we find and love, and we also have farms running with genetics we provide for them to grow. On top of it all, we work with the best design and packaging company in the world to showcase our partner farms hard work over at Sticker Farmer in Redwood City. Without Ben at the Sticker Farm, we’d never look so good. 

WB: What is your favorite food memory from childhood? What is your favorite food now? Do you cook? If so, who taught you? What does a typical breakfast look like to you? 

GotBars510: If I had to have a favorite food memory, it absolutely would be Dino Bites. I think the funniest part about then and now? My favorite food is still Dino Bites only nowadays, the best ones are made from my homie who is a Michelin Star recipient over at Rasoi in Burlingame. If I knew how to cook, I’d probably have more variations of them, but Asif has figured out the perfect recipe to keep Dino Bites as my #1 favorite food to eat. Other than Dino bites, I do love to eat my breakfast and if I had to pick my favorite, it’s simple, bacon, eggs, well-done hash browns and some toast.

WB: What is your passion? 

GotBars510: My passion is my job. It’s kinda a trip that I fell into the generation where prohibition ended and working in weed is what I live to do. My pops always told me, if you do what you love you’ll never work a day in your life, and it’s true. My passion is what I do on a daily basis and I am very grateful to be here for however long the universe sees fit.